Antithrombin concentrate (ATIIIC)

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

17 competitors in Hemophilia

#DrugCompanyPhaseTrials

1

Hemlibra

Roche

Approved

32

Videx

Bristol-Myers Squibb

Approved

13

Hivid

CConrado Roberto Hoffmann Filho

Approved

14

Epivir

GGlaxo Dba Glaxosmithkline

Approved

15

Zerit

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

16

Cyklokapron

JJ Molner

Approved

—7

Crixivan

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

18

Qfitlia

GGenzyme, a Sanofi Company

Approved

49

Antithrombin concentrate (ATIIIC)

Sanofi

Phase 3

310

Foscenvivint

KKiminori Kimura, MD

Phase 2

1Show 7 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hemophilia3 trials

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Active, not recruiting·Sanofi·Phase 3·NCT05662319·91 enrolled

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Recruiting·Sanofi·Phase 4·NCT06145373·20 enrolled

An Open-label, Parallel, Phase 3, Two-arm Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B With or Without Inhibitory Antibodies to Factors VIII or IX

Recruiting·Sanofi·Phase 3·NCT07285460·85 enrolled

Details

Drug Info

Related News